Eton Pharmaceuticals, Inc. - Common Stock (ETON)

Historical Holders from Q4 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ETON on Nasdaq
Shares outstanding
26,828,643
Price per share
$16.88
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
17,672,584
Total reported value
$384,025,414
% of total 13F portfolios
0%
Share change
+981,184
Value change
+$23,406,415
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
101
Price from insider filings
$16.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Eton Pharmaceuticals, Inc. - Common Stock (ETON) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
EcoR1 Capital, LLC 7.7% $25,059,688 1,981,003 EcoR1 Capital, LLC 31 Dec 2024
BlackRock, Inc. 5.7% $25,694,694 1,530,357 BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 5% $29,207,619 1,344,115 The Vanguard Group 30 Sep 2025
As of 30 Sep 2025, Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 101 institutional shareholders filing 13F forms. They hold 17,672,584 shares. of 26,828,643 outstanding shares (66%) .

Top 25 institutional shareholders own 58% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Opaleye Management Inc. 11% 2,860,000 0% 8.8% $62,147,800
EcoR1 Capital, LLC 7.6% 2,030,544 0% 2.1% $44,123,721
BlackRock, Inc. 6.4% 1,704,361 +11% 0% $37,035,765
VANGUARD GROUP INC 5% 1,344,115 +2.4% 0% $29,207,619
Nantahala Capital Management, LLC 4.4% 1,175,951 0% 1.6% $25,553,415
MORGAN STANLEY 2.2% 586,046 +15% 0% $12,734,780
GEODE CAPITAL MANAGEMENT, LLC 2.1% 574,030 -3.2% 0% $12,476,472
ROYAL BANK OF CANADA 1.8% 479,192 +9363% 0% $10,413,000
Westside Investment Management, Inc. 1.8% 472,540 -0.05% 1.6% $10,267,577
CANNELL CAPITAL LLC 1.7% 455,405 +17% 2.6% $9,895,951
STATE STREET CORP 1.6% 438,445 +36% 0% $9,527,410
THOMPSON SIEGEL & WALMSLEY LLC 1.6% 418,566 +9.8% 0.15% $9,095,000
JPMORGAN CHASE & CO 1.3% 351,417 +45% 0% $7,636,291
RENAISSANCE TECHNOLOGIES LLC 1.2% 324,621 -20% 0.01% $7,054,014
Divisadero Street Capital Management, LP 1.1% 298,000 -40% 0.3% $6,475,540
TWO SIGMA INVESTMENTS, LP 1.1% 286,421 +33% 0.01% $6,223,928
NORTHERN TRUST CORP 0.91% 245,051 -6.5% 0% $5,324,958
BNP PARIBAS FINANCIAL MARKETS 0.86% 229,790 0% 0% $4,993,337
UBS Group AG 0.82% 220,361 +3.7% 0% $4,788,445
Soleus Capital Management, L.P. 0.75% 200,000 -30% 0.23% $4,346,000
OBERWEIS ASSET MANAGEMENT INC/ 0.72% 192,360 0.16% $4,179,983
GOLDMAN SACHS GROUP INC 0.71% 190,164 +74% 0% $4,132,263
Lumbard & Kellner, LLC 0.66% 176,300 1.4% $3,830,999
TWO SIGMA ADVISERS, LP 0.63% 168,900 +67% 0.01% $3,670,197
Aristides Capital LLC 0.62% 167,587 0% 1.1% $3,641,666

Institutional Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 6,494 $109,389 +$109,389 1,687.87% 2
2025 Q3 17,672,584 $384,025,414 +$23,406,415 2,173% 101
2025 Q2 16,549,306 $235,826,915 +$35,134,980 1,425% 85
2025 Q1 14,123,114 $183,315,077 +$11,955,179 1,298% 85
2024 Q4 13,135,396 $174,958,469 +$42,338,288 1,332% 70
2024 Q3 9,507,414 $57,043,272 +$8,311,785 600% 48
2024 Q2 8,228,308 $27,068,977 +$3,401,842 329% 44
2024 Q1 7,182,688 $26,933,962 -$87,279 375% 43
2023 Q4 0 $0 -$87,987 0
2023 Q3 6,899,800 $28,769,681 +$3,931,368 417% 50
2023 Q2 5,976,427 $20,857,388 +$440,318 349% 33
2023 Q1 5,838,481 $22,478,563 +$148,360 385% 34
2022 Q4 5,937,571 $16,707,403 -$1,027,869 281.96% 31
2022 Q3 6,054,123 $12,712,785 +$549,663 210% 28
2022 Q2 5,271,693 $13,812,917 -$20,184 262.02% 25
2022 Q1 5,479,743 $23,886,686 +$176,962 436% 27
2021 Q4 5,432,030 $23,304,557 -$881,069 428.99% 28
2021 Q3 5,962,979 $32,576,856 -$4,921,316 504.01% 36
2021 Q2 6,841,117 $51,783,059 -$12,976,920 616.16% 43
2021 Q1 8,785,326 $67,962,804 +$241,245 731.92% 49
2020 Q4 8,725,390 $70,936,528 +$13,606,263 813% 45
2020 Q3 6,459,891 $51,033,819 +$510,955 789.86% 34
2020 Q2 6,803,798 $37,079,733 +$4,606,421 544.86% 40
2020 Q1 5,967,575 $24,469,000 +$13,632,158 410.16% 17
2019 Q4 2,623,150 $18,886,000 +$2,666,855 719.86% 13
2019 Q3 2,276,530 $14,386,000 +$3,212,366 631.58% 13
2019 Q2 1,767,833 $13,965,000 +$2,101,439 789.77% 10
2019 Q1 1,501,083 $12,008,000 +$2,816,107 800% 12
2018 Q4 1,151,824 $7,048,000 +$7,047,972 612% 11